Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Cited by
Items 101–200 of 542
Gazel, A., Rosdy, M., Bertino, B., Tornier, C., Sahuc, F., & Blumenberg, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700461 · Cited by 81
“INTRODUCTION Psoriasis is a paradigm of inflammatory diseases of the skin, which are mediated by white blood cells through an orchestrated interplay of secreted cytokines and chemokines that act on epidermal keratinocytes disrupting their differentiation and causing hyperplasia (Nickoloff and Nestle, 2004; Bowcock and…”
BackgroundPsoriasis and the metabolic syndrome
Alsufyani, M. A., Golant, A., & Lebwohl, M. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01307.x · Cited by 72
“This results in chronic T-cell activation, resulting in a persistent cycle of inflammation and formation of psoriatic plaques (3).”
BackgroundShibata, S., Tada, Y., Hau, C. S., Tatsuta, A., Yamamoto, M., Kamata, M., Karakawa, M., Asano, Y., Mitsui, H., Sugaya, M., et al. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10123.x · Cited by 71
Guttman‐Yassky, E., & Krueger, J. G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08135.x · Cited by 72
Nash, P. T., Thaçi, D., Behrens, F., Falk, F., & Kaltwasser, J. P. (2006) · Dermatology · doi:10.1159/000091251 · Cited by 68
“Psoriasis is a common skin condition that affects from 2 to 3p of the population worldwide [”
BackgroundMarble, D. J., Gordon, K. B., & Nickoloff, B. J. (2007) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2007.06.006 · Cited by 69
“To investigate the mechanisms of action by which anti-TNF therapy improves psoriatic lesions, a sequential series of skin biopsies obtained from six different individuals were procured for immunohistochemical analysis including PN skin and PP skin, before and after 2, 7, 28, and 84 days of treatment [3,8—10].”
BackgroundSelf-citationSingh, K., Gatzka, M., Peters, T., Borkner, L., Hainzl, A., Wang, H., Sindrilaru, A., & Scharffetter-Kochanek, K. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202399 · Cited by 69
Zhang, Y., Tu, C., Zhang, D., Zheng, Y., Peng, Z., Feng, Y., Xiao, S., & Li, Z. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430158 · Cited by 69
Herman, A., & Herman, A. P. (2016) · Planta Medica · doi:10.1055/s-0042-115177 · Cited by 74
Mahajan, R., Kaur, I., & Kanwar, A. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03486.x · Cited by 64
CCR6 as a possible therapeutic target in psoriasis
Hedrick, M. N., Lonsdorf, A. S., Hwang, S. T., & Farber, J. M. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.504716 · Cited by 68
“Besides TNF-a, IL-22 is of particular interest.”
BackgroundInfluentialMetabolic syndrome and skin: Psoriasis and beyond
Padhi, T., & Garima (2013) · Indian Journal of Dermatology · doi:10.4103/0019-5154.113950 · Cited by 102
“[36] Vascular endothelial growth factor-induced angiogenesis, found both in psoriasis and atherosclerosis, has also been proposed as a common link between the two conditions.”
Keratinocytes regain momentum as instigators of cutaneous inflammation
Nickoloff, B. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.01.001 · Cited by 61
Self-citationLee, Y., Jang, S., Min, J., Lee, K., Sohn, K., Lim, J.-S., Im, M., Lee, H.-E., Seo, Y., Kim, C. D., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.162 · Cited by 58
Wan, T. Y., Pan, J., Long, Y., Yu, K., Wang, Y., Pan, W., Ruan, W., Qin, M., Wu, C., & Xu, Y. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.050 · Cited by 60
Yuan, X., Li, N., Zhang, M., Lu, C., Du, Z., Zhu, W., & Wu, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109747 · Cited by 65
Gordon, K. B., Bonish, B. K., Patel, T. C., Leonardi, C., & Nickoloff, B. J. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06816.x · Cited by 60
Self-citationProtecting the boundary: the sentinel role of host defense peptides in the skin
Bernard, J. J., & Gallo, R. L. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0712-8 · Cited by 67
“Psoriasis affects up to 3% of the population and is characterized by the formation of typical scaly plaques and hypertrophic skin lesions [ 91 ].”
BackgroundCharles, J., Chaperot, L., Salameire, D., Domizio, J. D., Aspord, C., Gressin, R., Jacob, M., Richard, M., Béani, J., Plumas, J., et al. (2010) · European Journal of Dermatology · doi:10.1684/ejd.2010.0816 · Cited by 60
“The lymphocytic hypothesis is currently thought to be the most likely: autoreactive and constantly activated T lymphocytes produce cytokines that have pro-mitotic effects on keratinocytes (19).”
BackgroundExploring the link between cadmium and psoriasis in a nationally representative sample
Liaw, F.-Y., Chen, W.-L., Kao, T.-W., Chang, Y.-W., & Huang, C.-F. (2017) · Scientific Reports · doi:10.1038/s41598-017-01827-9 · Cited by 59
Defining Upstream Elements of Psoriasis Pathogenesis: An Emerging Role For Interferon α
Nestle, F. O., & Gilliet, M. F. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23923.x · Cited by 60
“dtd" [ ]> Psoriasis is a common chronic-relapsing immune-mediated pathology involving skin and joints of genetically predisposed individuals”
Self-citationOrchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action
Noor, A. A. M., Azlan, M., & Redzwan, N. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020498 · Cited by 66
Girardi, M., Duncan, K. O., Tigelaar, R. E., Imaeda, S., Watsky, K. L., & McNiff, J. M. (2005) · American Journal of Dermatopathology · doi:10.1097/01.dad.0000160982.75176.6c · Cited by 55
“For AGEP, the antigen is likely the drug or drug metabolite; for psoriasis, efforts are underway to try to identify relevant endogenous or exogenous T-cell antigens.(22,23) We found little similarity between the histology of patch tests in our 2 patients and the features of AGEP.”
Sanmiguel, J. C., Olaru, F., Li, J., Mohr, E., & Jensen, L. E. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.005 · Cited by 60
Molecular analysis of Malassezia microflora in the lesional skin of psoriasis patients
Amaya, M., Tajima, M., Okubo, Y., Sugita, T., Nishikawa, A., & Tsuboi, R. (2007) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2007.00343.x · Cited by 52
The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis
Nestle, F. O., & Conrad, C. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23488.x · Cited by 52
Self-citationPolypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis
Dolz‐Pérez, I., Sallam, M. A., Masiá, E., Morelló-Bolumar, D., del Caz, M. D. P., Graff, P., Abdelmonsif, D. A., Hedtrich, S., Nebot, V. J., & Vicent, M. J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.016 · Cited by 55
New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1
Blauvelt, A. (2007) · Expert Review of Dermatology · doi:10.1586/17469872.2.1.69 · Cited by 69
Plavina, T., Hincapie, M., Wakshull, E., Subramanyam, M., & Hancock, W. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.103770 · Cited by 56
“Complex cytokine signaling and interaction between epidermal keratinocytes andmononuclearleukocytesarethoughttoplaymajor roles in the pathogenesis of psoriasis ( 1 , 4). The severity of the disease is evaluated by the percentage of the body surface area affected or by the Psoriasis Area and Severity Index.”
BackgroundSerum interferon-gamma is a psoriasis severity and prognostic marker.
Abdallah, M., Hamid, M. F. A., Kotb, A. M., & Mabrouk, E. A.-Z. (2009) · PubMed · Cited by 60
Tohme, S. T., Yazdani, H. O., Sud, V., Loughran, P., Huang, H., Zamora, R., Simmons, R. L., Vodovotz, Y., & Tsung, A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800454 · Cited by 56
“Indeed, the therapeutic targeting of suspect inflammatory mediators has been moderately effective in certain chronic autoimmune diseases (23).”
BackgroundSun, C., Mathur, P., Dupuis, J., Tizard, R., Ticho, B., Crowell, T., Gardner, H., Bowcock, A. M., & Carulli, J. P. (2005) · Human Genetics · doi:10.1007/s00439-005-0115-8 · Cited by 49
“Psoriasis is a common inflammatory skin disease that affects 2–3% of the world’s population (Nickoloff and Nestle 2004).”
BackgroundRole of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin
Hanson, J., Gille, A., & Offermanns, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.003 · Cited by 57
“…that HCA2 is highly expressed in monocytes/macrophages and neutrophils (Carballo-Jane et al., 2007), which are enriched in the psoriatic skin (Nickoloff & Nestle, 2004) and that the HCA2 agonist has recently been shown to exert anti-inflammatory effects (Wu et al., 2010; Lukasova et al.,…”
BackgroundRole of LIM Kinases in Normal and Psoriatic Human Epidermis
Honma, M., Benitah, S. A., & Watt, F. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-12-1173 · Cited by 48
“Potential signals that could activate Stat3 are IL-6, IFN- , and EGF, all of which are up-regulated in psoriatic skin (Nickoloff and Nestle, 2004).”
BackgroundNakajima, A., Matsuki, T., Komine, M., Asahina, A., Horai, R., Nakae, S., Ishigame, H., Kakuta, S., Saijo, S., & Iwakura, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001227 · Cited by 48
Lorthois, I., Simard, M., Morin, S., & Pouliot, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071670 · Cited by 47
Kaštelan, D., Kaštelan, M., Massari, L. P., & Koršić, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.069 · Cited by 47
Zhang, K., Li, X., Yin, G., Liu, Y., Niu, X., & Hou, R. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08359.x · Cited by 46
Infliximab for the treatment of plaque psoriasis
Kalb, R. E. (2008) · Biologics · doi:10.2147/btt.s2116 · Cited by 47
“All rights reserved Biologics: Targets & Therapy 2008:2(1) 115–124 115”
Ovčina-Kurtović, N., & Kasumagić-Halilović, E. (2018) · Medical Archives · doi:10.5455/medarh.2018.72.410-413 · Cited by 47
“It induces antiapoptotic protein BCLx and alters the expression of the apoptotic catalytic enzymes, cathepsin D and zinc-ɑ2 glycoprotein, in psoriatic skin, thus promoting keratinocyte proliferation playing a major role in psoriasis pathogenesis (13).”
BackgroundEffect of Annurca Apple Polyphenols on Human HaCaT Keratinocytes Proliferation
D’Angelo, S., Porta, R. L., Napolitano, M., Galletti, P., Quagliuolo, L., & Boccellino, M. (2012) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0076 · Cited by 45
“14,15 18 Compounds that inhibit keratinocytes proliferation and modulate their differentiation are potentially useful in the treatment of psoriasis, because a balanced homeostatic control of growth and differentiation of this cellular line is crucial for recovery from psoriatic to normal epidermis.”
Retinoic acid contributes to the induction of IL-12-hypoproducing dendritic cells
Wada, Y., Hisamatsu, T., Kamada, N., Okamoto, S., & Hibi∥, T. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20934 · Cited by 51
Wan, T. Y., Pan, W., Long, Y., Yu, K., Liu, S., Ruan, W., Pan, J., Qin, M., Wu, C., & Xu, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s126210 · Cited by 45
What have we learned in dermatology from the biologic therapies?
Nickoloff, B. J., & Stevens, S. R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.059 · Cited by 49
Self-citationNarrowband UV-B Phototherapy, Alefacept, and Clearance of Psoriasis
Legat, F. J., Hofer, A., Gruber‐Wackernagel, A., Salmhofer, W., Quehenberger, F., Kerl, H., & Wolf, P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.8.1016 · Cited by 47
“P SORIASIS IS AN INFLAMMAtory skin disease that affects an estimated 2% to 3% of the world’s population.(1) The lesions typical of this disease— erythematous psoriatic plaques covered with silvery white scales—are clinical signs of chronic skin inflammation accompanied by hyperproliferation of keratinocytes and dermal…”
BackgroundImmunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity
Bachelez, H. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.09.025 · Cited by 44
Dysregulation of TAp63 mRNA and Protein Levels in Psoriasis
Gu, X., Lundqvist, E. N., Coates, P. J., Thurfjell, N., Wettersand, E. B., & Nylander, K. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700010 · Cited by 46
“INTRODUCTION Approximately 2–3% of the population worldwide suffers from psoriasis, a currently incurable disease with chronic and excessive inflammation of skin and joints (Nickoloff and Nestle, 2004).”
Backgroundde Groot, M., Teunissen, M. B. M., Ortonne, J. P., Lambert, J. R., Naeyaert, J. M., Picavet, D. I., Arreaza, M. G., Simon, J. S., Kraan, M. C., Bos, J. D., et al. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-007-0764-7 · Cited by 47
“Despite its common occurrence, the exact pathogenesis of psoriasis remains unclear and adaptations to the pathogenesis of this inXammatory disease are continuing [4, 9, 31, 35, 40 , 52].”
BackgroundPsoríase e obesidade: revisão de literatura e recomendações no manejo
Duarte, G. V., Follador, I., Cavalheiro, C. M. A., Silva, T. S., & de Oliveira, M. D. F. S. P. (2010) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962010000300009 · Cited by 44
Lorthois, I., Asselineau, D., Seyler, N., & Pouliot, R. (2017) · Mediators of Inflammation · doi:10.1155/2017/7215072 · Cited by 44
“Persistent activation of these cells would lead to the chronicization of psoriatic lesions, such as a vicious circle of inflammation [2, 22, 23].”
BackgroundCytokines in arthritis the 'big numbers' move centre stage
Gaston, H. (2007) · Rheumatology · doi:10.1093/rheumatology/kem203 · Cited by 49
Infliximab for the treatment of psoriasis
Kleyn, C. E., & Griffiths, C. E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.8.797 · Cited by 45
“TNF-α staining has been observed in macrophages and dermal DCs, and to a lesser extent in keratinocytes and Langerhans’ cells (epidermal DCs) [20,21].”
BackgroundImmunobiologics in the treatment of psoriasis
Chong, B. F., & Wong, H. K. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.01.006 · Cited by 55
Zhao, M., Lin, Z., Che, C., Cheng, C. H. K., & Tse, W.-P. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.20.5.663 · Cited by 43
Associations between Tumor Necrosis Factor-α Polymorphisms and Risk of Psoriasis: A Meta-Analysis
Zhuang, L., Ma, W., Cai, D., Zhong, H., & Sun, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068827 · Cited by 43
“Currently, the pathogenesis of psoriasis is still unclear and need further studies [1,3,4].”
BackgroundIL ‐22‐induced miR‐122‐5p promotes keratinocyte proliferation by targeting Sprouty2
Jiang, M., Ma, W., Gao, Y., Jia, K., Zhang, Y., Liu, H., & Sun, Q. (2016) · Experimental Dermatology · doi:10.1111/exd.13270 · Cited by 48
Arora, N., Shah, K., & Rai, S. P. (2015) · PROTOPLASMA · doi:10.1007/s00709-015-0829-y · Cited by 46
“…premature maturation of the keratinocytes of the skin, which is induced by a cascade of inflammatory mediators in the dermis, arising from dendritic cells, macrophages and T cells that play a significant role in the exacerbation of the disease (Palfreeman et al. 2013; Nickoloff and Nestle 2004).”
BackgroundLee, J., Kim, J., Park, S., & Lee, Y.-J. (2015) · Oncology Reports · doi:10.3892/or.2015.4332 · Cited by 45
“Psoriasis is a common chronic skin disease that is characterized by hyperproliferation and disrupted differentiation of keratinocytes (1-3).”
BackgroundTse, W.-P., Cheng, C. H. K., Che, C., & Lin, Z. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134080 · Cited by 41
“Affecting approximately 2% of the population worldwide, psoriasis is a common chronic inflammatory skin disease (Lebwohl, 2003; Nickoloff and Nestle, 2004).”
BackgroundWang, R., Wang, F., Cao, H., & Yang, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.045 · Cited by 41
Psoriasis and uveitis: links and risks
Fotiadou, C., & Lazaridou, E. (2019) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s179182 · Cited by 47
Bedini, C., Nasorri, F., Girolomoni, G., Pità, O. D., & Cavani, A. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07945.x · Cited by 41
Russell, S. E., Stefanska, A. M., Kubica, M., Horan, R. M., Mantovani, A., Garlanda, C., Fallon, P. G., & Walsh, P. T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300828 · Cited by 44
“Classically, psoriasis has come to be viewed as a T cell–driven autoimmune disorder due at least in part to its responsiveness to cyclosporine treatment (4) and also as Th1 cells, expressing IFN-g, were seen as the key drivers of disease pathogenesis (5, 6).”
BackgroundAdvances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies
Xu, J., Chen, H., Qian, H., Wang, F., & Xu, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01651-y · Cited by 43
Zhang, W., Song, Z., Bao, Y., Li, W., Yang, X., Wang, Q., Yu, C., Sun, L., Huang, Y., & Li, Y. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.001 · Cited by 40
Arbiser, J. L., Li, X., Hossain, C. F., Nagle, D. G., Smith, D. M., Miller, P., Govindarajan, B., DiCarlo, J., Landis‐Piwowar, K. R., & Dou, Q. P. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23809.x · Cited by 45
“The most common therapy for psoriasis is topical glucocorticoids (Wrone-Smith and Nickoloff, 1996; Stern, 1997; Lebwohl, 2004; Nickoloff and Nestle, 2004).”
BackgroundZampetti, A., Mastrofrancesco, A., Flori, E., Maresca, V., Picardo, M., Amerio, P., & Feliciani, C. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200423 · Cited by 41
“It is characterized by hyperproliferation, abnormal differentiation and maturation of the epidermis and a marked inflammation in both epidermis and dermis (2).”
BackgroundPoulin, Y. P., Papp, K. A., Wasel, N. R., Andrew, R. M., Fraquelli, E., Bernstein, G. M., & Chan, D. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04660.x · Cited by 39
Frers, R. A. K., Cosentino, V. L., Tau, J., Kerzberg, E. M., Urdapilleta, A., Chiocconi, M., Kogan, N. N., Losada, M. E. O., & Capani, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00139 · Cited by 42
“Epidemiological studies show a peak incidence of Ps between the second and third decades of life (2) and a global prevalence around 2–3% regardless of sex (3).”
BackgroundPlacebo Response in Two Long-Term Randomized Psoriasis Studies that were Negative for Rosiglitazone
Ellis, C. N., Barker, J. N., Haig, A. E., Parker, C. A., Daly, S. M., & Jayawardene, D. A. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708020-00005 · Cited by 38
Hüffmeier, U., Steffens, M., Burkhardt, H., Lascorz, J., Schürmeier-Horst, F., Ständer, M., Kelsch, R., Baumann, C., Küster, W., Mößner, R., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037515 · Cited by 39
Amigó, M., Payá, M., Rosa, S. D., & Terencio, M. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707394 · Cited by 41
“It controls and regulates the expression of numerous genes, and in doing so leads to cutaneous responses in psoriasis (Victor et al., 2003; Nickoloff and Nestle, 2004; Schottelius et al., 2004).”
BackgroundCox, N. H., & Coulson, I. H. (2004) · Wiley eBooks · doi:10.1002/9780470750520.ch5 · Cited by 38
Michalak-Stoma, A., Bartosińska, J., Kowal, M., Raczkiewicz, D., Krasowska, D., & Chodorowska, G. (2020) · Mediators of Inflammation · doi:10.1155/2020/7420823 · Cited by 39
“It is already recognized that psoriasis is not only skin specific but also a systemic disease, and many comorbidities are found as psoriasis related [3].”
BackgroundWeger, W., Hofer, A., Wolf, P., El‐Shabrawi, Y., Renner, W., Kerl, H., & Salmhofer, W. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00620.x · Cited by 36
Elewski, B. E., Leonardi, C., Gottlieb, A. B., Strober, B. E., Simiens, M. A., Dunn, M. E., & Jahreis, A. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07585.x · Cited by 35
Yoshida, A., Kanno, H., Watabe, D., Akasaka, T., & Sawai, T. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-007-0809-y · Cited by 35
“normal individuals [4], and the TNF inhibitors, such as inXiximub, adalimumab, and etanercept, are eVective in the treatment of psoriasis as well as rheumatoid arthritis [22, 29].”
BackgroundInfluentialHarberts, E. M., Heitmiller, K., & Gaspari, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-29785-9_13 · Cited by 33
Santilli, S., Kast, D. R., Grozdev, I., Cao, L. Y., Feig, R. L., Golden, J. B., Debanne, S. M., Gilkeson, R., Orringer, C. E., McCormick, T. S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0947-0 · Cited by 38
“A similar pattern of CD4+ T-cell activation through antigen presenting dendritic cells stimulate the proliferation of CD8+ T-cells, with activity of the T-helper 1 phenotype inflammation that prevails in both psoriasis and atherosclerosis [2, 4, 47, 48, 50, 51].”
BackgroundGenetic background of psoriasis.
Al‐Shobaili, H. A., Shahzad, M., Al-Marshood, A., Khalil, A., Settin, A., & Barrimah, I. E. (2010) · Europe PMC (PubMed Central) · Cited by 33
Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: a case report
Hübner, M., & Tenbaum, S. P. (2008) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2007.02634.x · Cited by 33
Abe, R., Yamagishi, S., Fujita, Y., Hoshina, D., Sasaki, M., Nakamura, K., Matsui, T., Shimizu, T., Bucala, R., & Shimizu, H. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.12.010 · Cited by 33
Colombo, D., Cassano, N., Altomare, G. F., Giannetti, A., & Vena, G. A. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300418 · Cited by 33
“Mailing address: Dr Delia Colombo, Ospedale Luigi Marchesi, Via Marchesi, 25, 20065, Milano, Italy Tel: ++39 02 6883804 Fax: ++39 02 965423 I8; e-mail: studio.deliacolombo@fastwebnet.it 1143 0394-6320 (2010) Copyright © by BIOUFE, s.”
A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo
Trachsel, E., Kaspar, M., Bootz, F., Detmar, M. J., & Neri, D. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700653 · Cited by 33
“Psoriasis is a chronic inflammatory skin disease that is associated with prominent involvement of angiogenesis (Bayliffe et al., 2004; Nickoloff and Nestle, 2004) in early plaque development (Christophers et al.”
BackgroundHochberg, M., Zeligson, S., Amariglio, N., Rechavi, G., Ingber, A., & Enk, C. D. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07628.x · Cited by 33
Shen, S., Lee, W., Yang, L., Tsai, H.-H., Yang, L., & Chen, Y. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01479.x · Cited by 32
Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice
Dimitris, D., Tomou, E., Karamani, C., Sfiniadakis, I., Ioanna, S. K., Aggeliki, L., Hatziantoniou, S., Rallis, M. C., & Skaltsa, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112208 · Cited by 43
Werner, B., Bresch, M., Brenner, F. M., & Lima, H. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2007.00800.x · Cited by 32
“In the past, psoriasis was thought to be a disease of keratinocytes because of its clinical appearance largely caused by epidermal changes because of excessive keratinocyte proliferation and abnormal differentiation.(1,2) It has been shown that the keratinocyte cell cycle time is reduced approximately eightfold in pso…”
BackgroundShiba, M., Kato, T., Funasako, M., Nakane, E., Miyamoto, S., Izumi, T., Haruna, T., & Inoko, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149316 · Cited by 39
Gamo, R., & López-Estebaranz, J. L. (2006) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(06)73342-7 · Cited by 31
Képíró, L., Széll, M., Kovács, L., Keszthelyi, P., Kemény, L. V., & Gyulai, R. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.11.006 · Cited by 35
MiR-330 inhibits IL-22-induced keratinocyte proliferation through targeting CTNNB1
Shen, H., Zeng, B., Wang, C., Tang, X., Wang, H., Liu, W., & Yang, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.005 · Cited by 35
“In particular, immune response mediated by T cells and keratinocytes has participated in the initiation and maintenance of psoriasis [3].”
Pan, M., Huang, Y., Zhu, X., Lin, X., & Luo, D. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10187 · Cited by 36
Yamaguchi, Y., Watanabe, Y., Watanabe, T., Komitsu, N., & Aihara, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.249 · Cited by 32
Lin, Z., Jiao, B. W., Che, C., Zuo, Z., Mok, C.-F., Zhao, M., Ho, W. K. K., Tse, W. P., Lam, K. Y., Fan, R. Q., et al. (2009) · Phytotherapy Research · doi:10.1002/ptr.3079 · Cited by 31
“Psoriasis, an infl ammatory skin disease affecting about 2–3% of the population worldwide (Lebwohl, 2003; Nickoloff and Nestle, 2004), is histologically characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes.”
Autoantibodies in psoriatic patients treated with anti‐TNF‐α therapy
Bardazzi, F., Odorici, G., Virdi, A., Antonucci, V. A., Tengattini, V., Patrizi, A., & Balestri, R. (2014) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12339 · Cited by 30
Mleczko, M., Gerkowicz, A., & Krasowska, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031767 · Cited by 31
Li, X., Hu, Y., He, B.-X., Li, L., Tian, Y., Xiao, Y., Shang, H., & Zou, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115785 · Cited by 31
Balato, N., Costanzo, L. D., Balato, A., Patruno, C., Scalvenzi, M., & Ayala, F. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10271.x · Cited by 33
Psoriasis: more than skin deep
Pittelkow, M. R. (2005) · Nature Medicine · doi:10.1038/nm0105-17 · Cited by 30
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.